;
Head of Healthcare, Thematic Global Equity
A global health challenge that demands sustained funding
;
”Our aim is to do well by doing good. In identifying the companies whose innovations have the potential to improve patient outcomes lies the key to generate long-term investment returns.
Scientific expertise at the heart of our investment approach
Our investment universe spans companies involved in detecting and understanding cancer, developing treatments and providing the technologies that support research and care. Scientific advances are expanding the range of solutions available, creating growth opportunities across the industry.
Clinical evidence
Our research starts with the products a company develops or markets. We examine clinical data and compare potential benefits with existing treatments and competing technologies.
Valuation discipline
We assess commercial prospects and valuation, seeking businesses where the quality of the science is matched by a credible investment case.
Sustainability analysis
ESG analysis complements this work by examining sustainability risks and how companies manage relationships with stakeholders.
Investing as the science evolves
Every clinical milestone can create winners and losers. Our specialist team continuously evaluates new evidence, its potential impact on patients and its commercial significance. By reassessing our convictions as the science evolves, we seek to capture opportunities across established healthcare leaders and emerging biotechnology innovators while managing clinical and valuation risks.
A team combining science and investment experience
Assessing opportunities in the oncology domain requires a detailed understanding of both the science and the businesses behind it.
Our healthcare team brings together investment expertise and scientific training, including PhDs in biotechnology. This combination helps us assess complex medical developments and their implications for companies.
Let’s write another story together
Find the right partner to invest in oncology
How do we identify investment opportunities in oncology? Discover this in this interview of Servaas Michielssens and Linden Thomson.
Servaas Michielssens
PhD, CFA, Head of Healthcare, Thematic Global Equity
Linden Thomson
CFA, Senior Portfolio Manager
Q&A
- ENInvesting in oncology: forewarned is forearmed
- FRUn investissement dans l’oncologie : mieux vaut prévenir que guérir
- NLEen belegging in oncologie: beter voorkomen dan genezen
- DEIn Onkologie investieren: vorbeugen ist besser als heilen
- ITInvestire nel settore oncologico: meglio prevenire che curare
- ESInversión en oncología
Figures are worth a thousand words
20 million
New cancer cases worldwide each year
20+ years
of healthcare and biotechnology investment experience
Since 2018
a dedicated investment strategy
Investing for tomorrow, and making a difference to cancer patients today
Our commitment to the fight against cancer extends to philanthropy. Through the Candriam Institute for Sustainable Development, we support organisations working on cancer research and prevention, as well as initiatives for patients and their families. A portion of the net management fees received by Candriam on this investment strategy is allocated to organisations fighting cancer, complementing the strategy’s investments in listed companies.[3] Between 2018 and 2025, the Institute donated €4.7 million to initiatives fighting cancer.[4]
Discover the initiatives supported by the Candriam Institute
Contact
Discuss oncology investing with our team
Main risks on our Fight Against Cancer Strategy
The most significant risks on this strategy are:
- Risk of loss of capital
- Equity risk
- Foreign exchange risk
- Risk associated with derivative financial instruments
- Liquidity risk
- Emerging countries risk
- ESG Investment risk
- Counterparty risk
- Risk related to external factors
- Concentration risk
- Sustainability risk
- Risk of changes to the benchmark index by the index provider
- Hedging risk of the share classes
For further details on risks associated with investing in the promoted strategy, a general description and explanation of the various risk factors is available in the section Risk Factors of the relevant regulatory documents.
[1] Source: World Health Organization (WHO)
[2] Diagnoses during 2015-2021, American Cancer Society 2026/ © Copyright American Cancer Society, 2026, FDA, Candriam
[3] 10% of the net management fees received by Candriam on this strategy are allocated to associations and/or organizations fighting against cancer by being active in the field of scientific research and or the development of treatments, in social projects for families, in information, in public awareness and/or in cancer prevention, as set out in the section entitled Investment objectives of the regulatory documents.
[4] Donations between 2018 (creation of the Candriam Institute for Sustainable Development) and 2025.
-
World Cancer Day : Innovation, Hope, and the Future of Oncology
Precision oncology is entering a new era—one defined by earlier detection, personalised treatment, and the growing potential for long-term remission or cure. -
From uncertainty to growth: why invest in healthcare?
As we enter the month of October, investors are faced with an obvious question: is the time right for new investments in the oncology sector? Pasquale Sansone, Senior Biotechnology Analyst, shares his analysis and convictions. -
Why oncology remains a key investment opportunity
The investment landscape is marked by persistent macroeconomic uncertainties, uneven growth, and heightened geopolitical risks. Despite attractive earnings growth, healthcare has also been under pressure due to regulatory restructuring, drug pricing debates, budget constraints, and tariff concerns. -
Precision Oncology Powered by AI: A New Era for Cancer Treatment
Have you heard about radiotheranostics? This new field in medicine combines diagnosis and therapy. It involves using specially designed radioactive compounds that can both identify cancer cells and deliver targeted radiation therapy to destroy them. This is one of the latest developments of precision medicine, a domain that offers fascinating prospects in both early detection and specific treatment. -
Five Reasons to Invest in the Oncology Market Today
The investment landscape is evolving against a backdrop of rising economic uncertainties and a cautious market environment, further complicated by geopolitical tensions and upcoming elections. -
Advances in Healthcare and Oncology: A Pink October Perspective
Good news! The five-year survival rate for women diagnosed with breast cancer in the United States is now 90%[1]. Unfortunately, when looking at other statistics, the outlook worrying: one in eight women will develop an invasive form of breast cancer during their lifetime. In 2020, two million new cancer cases were diagnosed worldwide. Breast cancer is the most common cancer type among women and the second deadliest, following lung cancer. To better understand the urgency of treatments: in 2020, 685,000 women lost their lives from breast cancer. -
World Cancer Day 2023
And we would rather not have to go through this – which would mean we won the battle and cancer is curable. -
World Cancer Day: How PRISM is helping to Close the Gap
The Candriam Institute provides financial support to the PRecISion Medicine Institute. The PRISM technology aims to save an additional 200,000 lives each year by identifying the unique molecular characteristics of each patient's cancer.
